Comparing of Different Biomarkers From Vena Rectalis Superior and Vena Cubiti in Patients Undergoing Low Anterior Resection for Rectum Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01706809

Enrollment

Registered

2012-10-15

Start date

2011-09-30

Completion date

2015-12-31

Last updated

2014-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal Cancer

Brief summary

The primary aim of the present study is to investigate different biomarkers like VEGF, EVGF and others ability to predict time to recidive and progressions free survival.

Detailed description

Patients undergoing LAR for rectum cancer is subjected. Preoperative blood samples from vena rectalis superior and vena cubiti is collected, as well as biopsies from tumor. Preoperative and after 3 month peripheral blood samples is collected. A total of 50 patients will be included in this study. The study is approved by the local scientific ethical committee No. S-20100006

Interventions

OTHERblood sampels from vena rectalis superior and vena cubiti

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histological verified cancer * The cancer must be located in rectum maximum of 15 cm. * Age above 18

Exclusion criteria

* Disseminated cancer * Perioperative radio-chemotherapy * Laparoscopy surgery

Design outcomes

Primary

Measure	Time frame
The primary aim of the present study is to investigate different biomarkers like VEGF, EVGF and others ability to predict time to recidive and progressions free survival.	after the study is complete

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026